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Background: Myelodysplastic syndrome (MDS) eventually transforms into acute leukemia (AL) in about 30% of
patients. Hypermethylation of the inhibitor of DNA binding 4 (ID4) gene may play an important role in the initiation
and development of MDS and AL. The aim of this study was to quantitatively assess ID4 gene methylation in MDS
and to establish if it could be an effective method of evaluating MDS disease progression.
Methods: We examined 142 bone marrow samples from MDS patients, healthy donors and MDS-AL patients using
bisulfite sequencing PCR and quantitative real-time methylation-specific PCR. The ID4 methylation rates and levels
were assessed.
Results: ID4 methylation occurred in 27 patients (27/100). ID4 gene methylation was more frequent and at higher levels
in patients with advanced disease stages and in high-risk subgroups according to WHO (P < 0.001, P < 0.001, respectively)
and International Prognostic Scoring System (IPSS) (P = 0.002, P = 0.007, respectively) classifications. ID4 methylation levels
changed during disease progression. Both methylation rates and methylation levels were significantly different between
healthy donor, MDS patients and patients with MDS-AL (P < 0.001, P < 0.001, respectively). Multivariate analysis indicated
that the level of ID4 methylation was an independent factor influencing overall survival. Patients with MDS
showed decreased survival time with increased ID4 methylation levels (P = 0.011, hazard ratio (HR) = 2.371).
Patients with ID4 methylation had shorter survival time than those without ID4 methylation (P = 0.008).
Conclusions: Our findings suggest that ID4 gene methylation might be a new biomarker for MDS monitoring
and the detection of minimal residual disease.
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Myelodysplastic syndrome (MDS) is a heterogeneous
group of clonal stem cell disorders characterized by ab-
normal differentiation and maturation of myeloid cells.
The natural history of these syndromes may range from
a chronic course, spanning many years, to a rapid
course of leukemic progression [1], and 30% of cases of
MDS eventually transform into acute leukemia (AL)
[2]. In myelodysplasia, malignant transformation at the
level of a myeloid stem cell can result in chromosomal* Correspondence: ylmedsci@163.com
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unless otherwise stated.abnormalities that act as signatures of the disease and
can be identified in precursor cells giving rise to granu-
locytes, monocytes, red cells, and platelets [3]. For the
development of the leukemic clone, further genetic
events are required for the rapid expansion of leukemic
blasts [4]. Many people regard MDS as the first stage of
a hematological myeloid malignancy and consider MDS
as the best intermediate stage research model for AL.
MDS pathogenesis and its frequent progression to AL
are associated with aberrant cell clones with little ability
for differentiation but with a high ability to proliferate
[5,6]. This aberration of MDS is believed to be a multi-
step process of aberrant expression of the tumor sup-
pressor gene (TSG) requiring both aberrant genetic andhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Table 1 Clinical characteristics of the study groups






















NBM, normal bone marrow; MDS, myelodysplastic syndrome; AL, acute
leukemia; RA, refractory anemia; RARS, refractory anemia with ringed
sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS,
refractory cytopenia with multilineage dysplasia and ringed sideroblasts; RAEB,
refractoryanemia with excess of blasts; IPSS, International Prognostic
Scoring System.
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thylation of the gene promoter region [4,7-11]. Previous
studies have demonstrated that abnormal hypermethyla-
tion of many TSG promoter regions such as CpG islands
are associated with MDS development and progression
[12-17]. MDS patients treated with hypomethylating
agents such as 5-azacytidine and decitabine achieved
high overall response rates and hematological improve-
ment rates [3,18-22]. In addition, it is well known that
with the development of MDS, there are increases in ab-
normal blasts in bone marrow, which may be the result
of abnormal expression of TSG in terms of cell cycle,
cell differentiation, and cell proliferation.
To date, the role of aberrant promoter methylation in
MDS has not been investigated exhaustively, and previ-
ous studies have mainly focused on cycling-dependent
kinase inhibitors even if other genes have been found to
be targeted by aberrant hypermethylation in MDS. For
example, hypermethylation of the inhibitor of DNA
binding 4 (ID4) gene may play an important role in
hematological [23] and solid cancers [24]. ID4 contrib-
utes to cell differentiation and proliferation [24-28], and
abnormal methylation of the ID4 gene in hematological
cancers plays an important role in diagnosis and progno-
sis [26,29]. Aberrant methylation of the ID4 promoter
region is associated with invasiveness, growth, and recur-
rence of many solid tumors [26,29-34] and with initi-
ation and progression in hematological cancers including
leukemia and lymphoma [23,26,29,35]. However, the
methylation status of the ID4 gene in MDS patients and its
clinical significance are poorly described.
Due to the high frequency of DNA methylation in
MDS and its involvement in leukemia transformation,
we hypothesized that the analysis of DNA methylation
levels is a potential predictor for prognosis. This was
achieved using a rapid and quantitative methylation de-
tection methodology based on real-time PCR. The aim
of the present study was to investigate the clinical im-
pact of ID4 gene methylation on MDS prognosis in




We selected 142 bone marrow samples harvested from
the ilium by osteostixis from individuals who visited the
Chinese PLA General Hospital between May 2007 and
June 2010. Samples for bisulfite sequencing study corre-
sponded to bone marrow specimens from a healthy
donor (age: 45 years, gender: male), bone marrow from a
patient with MDS who was diagnosed with refractory
anemia (MDS-RA) (age: 40 years, gender: male) and bone
marrow from a patient with acute myeloid leukemia
(MDS-AML) (M6) (age: 42 years, gender: male). Bothpatients with MDS and AML were diagnosed according to
the World Health Organization (WHO) criteria. The
prognostic score for each patient was calculated using the
International Prognostic Scoring System (IPSS) [36]. For
methylight analysis, we selected bone marrow samples
from 100 patients with MDS, 20 healthy donors and 22
patients with MDS-AML from our institution. Ten sam-
ples in each group were randomly selected to assess the
correlation between bisulfite sequencing PCR (BSP) and
methylight; methylight was performed only in patients
with high BSP results because of the detection threshold
of methylight. Patients’ characteristics are shown in
Table 1. Normal bone marrow samples (n = 20) were ob-
tained for negative controls. In addition, for further posi-
tive and negative controls, we included malignant
hematological cell lines including NB4 (acute leukemia
cell line) and 293 (renal cell line) obtained from the
American type culture collection (ATCC).
The study was approved by the local internal review
boards and ethics committees. Written informed con-
sent was obtained from all subjects.
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DNA was extracted using a Genomic DNA extraction
kit (Promega, Madison, WI, USA). The ID4 gene DNA
sequence was obtained from the National Center for
Biotechnology Information (NCBI).Bisulfite sequencing PCR
Sodium bisulfite treatment was provided to 1 μg of each
DNA sample using the Epi bisulfite kit (Qiagen, Venlo,
Limburg, Netherlands) according to the manufacturer’s
instructions. Bisulfite-treated genomic DNA was altered
so that all unmethylated CpG sites were converted to
TG, and methylated CpG sites remained CG.
The methylated or unmethylated status of the pro-
moter region of the ID4 gene was determined by PCR
amplification of the bisulfite-treated genomic DNA using
specific PCR primers (Table 2 and Figure 1).
The PCR conditions were 95°C for 15 min, followed
by 40 cycles of 50 s at 94°C, 45 s at 53°C, and 60 s at 72°
C, and a final extension of 72°C for 10 min. The PCR re-
action mixture contained 2 μl of bisulfite-modified
DNA, 1 μl of 25 mM dNTPs, 2.5 μl of 10× Herman’s
buffer, 1.5 μl of 10 pmol/μl of each primer, and 0.5 μl of
Hotstar Taq DNA Polymerase (Invitrogen, Carlsbad, CA,
USA), for a final volume of 25 μl.
PCR products were analyzed on a 1.5% agarose gel,
and then were purified using a QIAquick Gel Extraction
Kit (Qiagen) and transformed into Escherichia coli cells
using the pGEM-T easy vector (Promega). Ten individ-
ual clones were selected for vector extraction by QIA-
prep Spin Mini Prep Kit (Qiagen). Vector DNA samples
were sequenced by Invitrogen.Methylight
After bisulfite treatment and purification, the promoter
of the ID4 gene was evaluated by methylight. The
primers and the probe for methylight were located in









ID4, inhibitor of DNA binding 4; BSP, bisulfite sequencing PCR.gene probe had 10 CpG sites. The primers and the in-
ternal control gene MYOD1 probe had no CpG sites
[37]. Both the ID4 gene and MYOD1 gene probes were
labeled with 6-fluorescein amidite (FAM) at the 5′ end
and the quencher tetramethylrhodamine (TAMRA) at
the 3′ end. All primers and probes were synthesized by
Invitrogen. The primers and probes used for PCR are
shown in Table 2.
The 20-μl reaction mixture included 2.5 μmol of each
primer, 1.25 μmol of probe, 2 μl of bisulfite-converted
DNA, and 10 μl of mix buffer (Qiagen). Conditions were
as follows: 95°C denaturation for 10 min, followed by
45 cycles at 95°C denaturation for 30 s, and 57°C anneal-
ing and extension for 1 min. Methylight PCR reactions
were performed in an MX3000p device (Stratagene, La
Jolla, CA, USA). To control the accuracy of the methy-
light reactions, we used DNA from NB4 cell lines previ-
ously known to be methylated and DNA from 293 cell
lines previously known to be unmethylated for the genes
being analyzed.
The methylation levels of the ID4 gene were calculated
individually using the relative quantification method.
The standard sample was made of bisulfite-treated DNA
from the NB4 cell line. A standard curve was produced
for ID4 and MYOD1 (as the internal control gene) [37]
by a 10-fold dilution series of four different plasmid con-
centrations. Every run had a standard curve. The posi-
tive samples had amplification curves, but negative
samples had no amplification curves.Statistical analysis
Statistical analysis was performed using SPSS 18.0 for
Windows (IBM, Armonk, NY, USA). We used the chi-
square test or the Fisher’s exact test to evaluate categor-
ical data. The Mann–Whitney non-parametric test was
used for comparisons of continuous data.
The Spearman’s rank correlation was used for correl-






Figure 1 Methylation frequency of CpG sites and association between the ID4 methylation percentage. (A) Methylation frequency of CpG
sites in the ID4 gene in NBM, MDS and MDS-AL. Filled circle and empty circle represent one methylated CpG site (CG) and unmethylated CpG site
(TG), respectively. P < 0.001. (B) Association between the ID4 methylation percentage using bisulfite sequencing PCR and methylight. Using linear
regression, we obtained a goodness of fit of r2 = 0.7168. Using an exponential curve, the goodness of fit was r2 = 0.8485. AL, acute leukemia; MDS,
myelodysplastic syndrome; NBM, normal bone marrow; TSS, transcriptional start site.
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until the day of death or the last follow-up date (censored
on 31 December 2012). OS was analyzed according to the
Kaplan-Meier method and the log-rank test. The Cox pro-
portional hazard regression model was used for the adjust-
ment of independent prognostic factors in multivariate
survival analysis. Two-tailed P values ≤ 0.05 were consid-
ered statistically significant.Results
Detection of CpG methylation frequency by BSP
We detected the methylation status of bone marrow
samples from one healthy donor, one MDS patient, and
one AML patient using BSP. Ten clones from every
bone marrow sample were chosen. For the ID4 gene,
every clone had 48 CpG sites. The frequency of positive
sites in the ID4 gene was 2.08% (10/480) for the normal
bone marrow (NBM) sample, 41.46% (199/480) for theMDS patient sample, and 70.00% (336/480) for the
MDS-AL patient sample (Figure 1A).Comparison of ID4 gene methylation status in NBM, MDS,
and MDS-AL by methylight
ID4 methylation positivity rates were different among
the NBM (0%), patients with MDS (27%) and patients
with MDS-AL (68.18%). ID4 methylation levels were
also different among the NBM [0 (0 to 0)], patients with
MDS [0.21 (0 to 3.79)], and patients with MDS-AL [0.57
(0 to 1.43)]. Both methylation positivity rates and methy-
lation levels were significantly different between healthy
donors, patients with MDS and patients with MDS-AL
(P < 0.001, P < 0.001, Table 3). There was an association
between the ID4 methylation percentage using BSP and
methylight. Using linear regression, we obtained a good-
ness of fit of r2 = 0.7168. Using an exponential curve, the
goodness of fit was r2 = 0.8485 (Figure 1B).
Table 3 ID4 methylation status of NBM, MDS, and AML
NBM MDS MDS-AL P value
Patients (N) 20 100 22
ID4 methylated 0 27 15 <0.001
ID4 methylated level 0 (0 to 0) 0.21 (0 to 3.79) 0.57 (0 to 1.43) <0.001
NBM, normal bone marrow; MDS, myelodysplastic syndrome; AL, acute leukemia; ID4, inhibitor of DNA binding 4.
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and correlation with clinical characteristics
As summarized in Table 4, 27 patients showed ID4 gene
hypermethylation. Patients with ID4 gene methylation
had higher levels of white blood cell (WBC) counts and
bone marrow blast counts than those without (P = 0.036,
P = 0.001). ID4 methylation levels were correlated with
bone marrow blast counts in patients with MDS (r =
0.388, P < 0.001, Figure 2). There were no significant dif-
ferences in other clinical features, such as age, sex, initial
hemoglobin levels, and platelet counts, between the
MDS patients with and without ID4 gene hypermethyla-
tion (P > 0.05).
Association between ID4 gene methylation status (by
methylight) and MDS subtypes
As summarized in Table 5, those who harbored ID4 gene
hypermethylation according to WHO subtypes included
four (9.76%) of the 41 patients with RA, four (18.18%) of
the 22 patients with refractory cytopenia with multiline-
age dysplasia (RCMD), one (14.29%) of the 7 patients
with refractory anemia with ringed sideroblasts (RARS),
eleven (52.38%) of the 21 patients with refractory anemia
with excess blasts (RAEB)-1, and seven (77.78%) of the 9
patients with RAEB-2. There was a significant difference
in the rates of ID4 gene methylation between the differ-
ent WHO subtypes (P < 0.001). MDS patients with high-
risk subtypes (RAEB-1 and RAEB-2) had a significantly
higher incidence of ID4 gene methylation (60%) than
those with low-risk subtype (RA, RCMD, and RARS,
12.86%, P < 0.001). Another risk stratification, the IPSSTable 4 Correlation between clinical characteristics and ID4 g
Total Meth
Patients (N) 100 27
Age (years) 46 (13 to 86) 51 (3
Sex (male/female) 55/45 14/13
WBC (×109/L) 4.12 (0.35 to 25.9) 3.95 (
Hemoglobin (g/L) 86 (44 to 140) 76 (5
Platelet (×109/L) 84.19 (1 to 459) 98.43
BM blasts (%) 2.99 (0 to 17.2) 6.1 (0
BM, bone marrow; WBC, blood cell counts.(which weights the effects of blast quantity, karyotype,
and cytopenia), also showed a different methylation posi-
tivity rate between the low-risk group (8.33%, 2/24 pa-
tients with low and intermediate risk (INT) 1) and the
high-risk group (63.64%, 7/11 patients with INT 2 and
high) (P = 0.002). As summarized in Table 5, ID4 gene
methylation levels was used to evaluate the WHO sub-
types (P < 0.001), WHO risk stratification (P < 0.001),
and IPSS risk stratification (P = 0.007). However, both
the ID4 gene methylation positivity rates and methyla-
tion levels of the MDS patients with different karyotypes
showed no significant differences (P = 1.000, P = 1.000).
Prognostic factors analysis
A multivariate Cox survival analysis of age, sex, hemoglobin
levels, platelet (PLT) counts, WBC counts, bone marrow
blast levels, subtypes by IPSS and ID4 methylation level on
OS was performed for the MDS patients (Table 6). Results
showed that sex, age, IPSS risk group, and ID4 methylation
levels were significant independent risk factors of poor OS
in patients with MDS. IPSS risk group was the strongest
factor on OS (HR = 7.374).
The estimated median survival time of all patients was
39.0 months. Using the IPSS risk groups, patients with a
higher risk had a shorter median survival (51.4 months
for the low risk group, 42.1 months for the INT 1 risk
group, 35.2 months for the INT 2 risk group, and
22.0 months for the high risk group).
ID4 methylation level was an independent factor af-
fecting OS. Patients with MDS showed poor survival
with increased ID4 methylation levels (P = 0.011, HR =ene methylation
ylated Unmethylated P value
73
8 to 83) 44 (13 to 86) 0.100
41/32 0.700
0.352 to 20) 4.18 (1.05 to 25.9) 0.036
2 to 114) 89 (44 to 140) 0.088
(12 to 459) 90.16 (1 to 381) 0.656
to 17.2) 1.8 (0 to 11.6) 0.001
Figure 2 Methylation level of the ID4 gene according to the percentage of bone marrow blasts. ID4 gene methylation levels increase with
the number of bone marrow blasts (r = 0.388, P < 0.001). ID4, inhibitor of DNA binding 4.
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sex were significant predictors of OS (P = 0.007, HR =
6.277 and P < 0.001, HR = 4.119, respectively), whereas
marrow blast levels did not show statistical significance
(P = 0.245). Patients with ID4 methylation had shorter
survival time than those who had unmethylated ID4 (P =
0.008, Figure 3). There was a significant difference in the
median survival between the methylated ID4 group
and the unmethylated group (30.2 and 44.3 months,
respectively).
Sequential analysis of ID4 gene methylation status during
MDS evolution
For one patient, bone marrow samples were available
over five stages. With a follow-up time of 20 months,
this patient underwent a disease progression from MDS-
RA and MDS-RAEB to AL and transplantation. ID4
methylation levels of MDS-RA, MDS-RAEB, AL, and
days 37 to 200 after transplantation were 0.45, 0.86, 1.47,
and 0, respectively. ID4 gene methylation levels changed
with the number of bone marrow blasts. Four additional
patients with MDS with sequential samples were in the
same situation: ID4 gene hypermethylation reflected dis-
ease stage and became negative after transplantation or
demethylation treatment, and this was associated with
bone marrow blasts (Figure 4).
Discussion
The aim of this study was to investigate the biological
significance and the prognostic relevance of the ID4gene methylation status and methylation levels in MDS
patients. Our results, which used for the first time quan-
titative real-time methylation-specific PCR (methylight)
for ID4 gene methylation detection, indicated that aber-
rant methylation of the ID4 gene may play an important
role in the prognosis of MDS.
Firstly, we detected the methylation of the ID4 gene
promoter region CpG sites using BSP. There was a sharp
increase in methylation positivity rates from NBM, MDS
to AL, which corresponded with the methylight result.
As the intermediate stages of AL, MDS had moderate
methylation levels of the ID4 gene, intermediate to those
for NBM and AL. This is a clear indication that ID4
methylation detection could be used to monitor MDS
progression.
In this study, 27 patients showed aberrant ID4 gene
methylation, which was present in each WHO subtype
of MDS, with increasing amounts in ascending order of
RA, RCMD, RARS, RAEB-1, and RAEB-2. Methylation
occurred more frequently in both high-risk WHO and
IPSS subtypes of MDS. Wang et al. reported that ID4
methylation was present in 35.4% of adult patients newly
diagnosed with MDS and occurred more frequently in
advanced-stage MDS by methylation-specific PCR (MSP)
[35]. These discrepancies may be the result of the different
methods used. Besides the methylation positivity rate,
methylation levels were also used to evaluate the relation-
ship with the WHO subtypes and IPSS. ID4 gene hyper-
methylation occurred in more advanced stage of MDS
samples, as well as with higher methylation levels. As an
Table 6 Multivariate analysis of prognostic factors for
overall survival
P value HR (95% CI)
Age (years) 0.007 6.277 (2.417 to 16.300)
Sex (male/female) <0.001 4.119 (1.466 to 11.578)
Hemoglobin (g/L) 0.731 0.997 (0.983 to 1.012)
WBC (×109/L) 0.738 1.014 (0.935 to 1.100)
Platelet (×109/L) 0.823 1.000 (0.995 to 1.004)
BM blast (%) 0.245 1.041 (0.973 to 1.114)
IPSS risk group <0.001 7.374 (3.746 to 14.518)
ID4 methylation level 0.011 2.371 (1.221 to 4.602)
BM, bone marrow; WBC, blood cell counts; IPSS, International Prognostic Scoring
System; ID4, inhibitor of DNA binding 4, 95% CI, 95% confidence interval.
Table 5 Association between ID4 gene methylation status and MDS subtypes
Total Methylation level P value Methylated P value
Patients (N) 100 27
IPSS karyotype 37 0.360 9 0.298
Good 22 0.14 (0 to 2.72) 4
Intermediate 9 0.24 (0 to 0.80) 4
Poor 6 0.04 (0 to 0.24) 1
BM blast (%) 0.098 <0.001
<5 75 0.47 (0 to 1.51) 10
5 to 10 13 0.84 (0 to 3.79) 8
11 to 19 12 1.03 (0 to 2.80) 9
IPSS cytopenias 0.734 0.787
0/1 22 0.24 (0 to 2.80) 5
2/3 78 0.20 (0 to 3.79) 22
IPSS risk group 35 0.007 9 0.002
Low-risk (low/int-1) 24 0.03 (0 to 0.76) 2
High-risk (Int-2/high) 11 0.43 (0 to 2.72) 7
WHO subtype 100 27
Risk 0.000 <0.001
Low risk 70 0.06 (0 to 1.51) 9
High risk 30 0.54 (0 to 3.79) 18
Subtype 0.000 <0.001
RA 41 0.04 (0 to 0.59) 4
RCMD 22 0.06 (0 to 0.76) 4
RARS 7 0.22 (0 to 1.51) 1
RAEB-1 21 0.41 (0 to 3.79) 11
RAEB-2 9 0.8 (0 to 2.8) 7
RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS, refractory cytopenia
with multilineage dysplasia and ringed sideroblasts; RAEB, refractory anemia with excess of blasts; IPSS, International Prognostic Scoring System. Good: normal, −Y,
del(5q) or del(20) as the sole abnormality; poor: complex (≥3 abnormalities) or chromosome 7 anomalies.
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may increase the risk of disease progression in patients
with MDS patients.
Many studies have reported that more bone marrow
blasts in patients with MDS provide more opportunities
for leukemia transplantation [38]. Previously, it was
shown that both bone marrow blasts and ID4 methyla-
tion were independent factors for leukemia-free survival
(LFS) estimation in MDS patients [35]. In our study, not
only ID4 methylation levels had high correlation with
bone marrow blasts, but there was also a significant dif-
ference between the ID4 methylated and unmethylated
groups, in terms of bone marrow blasts. This hinted that
ID4 methylation levels may be a substitute for the de-
gree of dysplastic cells for interpreting pathogenetic con-
ditions. After treatment by either transplantation or
demethylation, ID4 gene methylation in all sequential
samples was negative, corresponding to decreased bone
marrow blasts. To some extent, ID4 gene methylation
Figure 4 Relationship between ID4 methylation levels and BM
blasts during disease status in five MDS patient samples at
different disease stages. ID4 gene methylation levels increased or
decreased with the number of bone marrow blasts. (A) ID4
methylation level of one patient during different disease stages
MDS-RA, MDS-RAEB, AML, day 37 to day 200 after transplantation.
(B) ID4 methylation level of four patients in different disease stages.
(C) BM blasts of four patients in different disease stages. Stage 1: new
diagnosis; stage 2: the first period of demethylation treatment for
patient 2 and patient 3 and 1 month after transplantation for patient 4
and patient 5; stage 3: the second period of demethylation treatment
for patient 2 and patient 3 and 2 months after transplantation for
patient 4 and patient 5. AML, acute myeloid leukemia; ID4, inhibitor
of DNA binding 4; MDS-RA, MDS with refractory anemia; MDS-RAEB,
MDS with refractory anemia with excess blasts.
Figure 3 Overall survival of MDS patient groups for ID4 gene
with and without methylation. Patients with ID4 methylation had
a shorter survival than those without ID4 methylation (P = 0.008).
ID4, inhibitor of DNA binding 4.
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ease (MRD) detection. In addition, the detection of ID4
gene methylation could offer some guidance to MDS
treatment stratification.
In our multivariate analysis, IPSS risk groups was an
independent factor that affected the OS of patients with
MDS. This finding was consistent with their clinical
state. Our investigations indicated that the ID4 methyla-
tion levels were higher in advanced-stage MDS, indicat-
ing that ID4 methylation might be a molecular event
playing an important role in the progression of MDS. In
our study, ID4 methylation levels were considered to
affect the OS of MDS patients. Meanwhile, patients with
ID4 methylation had a shorter survival time. These re-
sults hinted that ID4 methylation levels may be an inde-
pendent prognostic factor for overall survival.
Our results revealed that while there was no signifi-
cant correlation between ID4 gene methylation and gen-
etic abnormalities, taken together they may offer greater
potential as biomarkers for MDS. As previously reported,
the occurrence and progression of cancers includes both
genetic and epigenetic alterations [39,40], and for epigen-
etic alterations, ID4 gene methylation could be used for
auxiliary diagnosis and prognosis of MDS patients without
significant genetic alterations. Combining these two
mechanisms could cover more scope for disease monitor-
ing, treatment effect evaluation and MRD detection.
The present study investigated the status and levels of
ID4 gene methylation in seven patients with MDS at dif-
ferent stages of MDS to directly interpret the closecorrelation of disease evolution with ID4 gene methyla-
tion for the first time. In terms of disease progression,
ID4 gene methylation status of one sequential MDS pa-
tient sharply increased from MDS-RA and MDS-RAEB
to AML. After transplantation, ID4 methylation was
negative, supporting the role of ID4 gene methylation in
MRD progression.
It is noteworthy that drugs with demethylating activity
are increasingly used and studied in hematological ma-
lignancies [41-43]. One could speculate that the pres-
ence of increased DNA methylation levels in MDS in
clinical remission might provide a rationale for the use
Kang et al. European Journal of Medical Research  (2015) 20:16 Page 9 of 10of these drugs in affected patients. Further clinical stud-
ies are necessary to clarify this possibility and to define
the accuracy of methylation MRD estimation.
Conclusions
Our findings provide evidence that aberrant DNA methy-
lation is present in MDS patients and can potentially be
used for prognosis. These findings may offer the possibil-
ity of prognostic estimation for many patients who cur-
rently lack adequate markers.
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